DDInter222 DDInter1676
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib. Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Bortezomib {u} (Compound) resembles {v} (Compound) Aspartame
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Bortezomib {u} (Compound) treats {v} (Disease) hematologic cancer
Bortezomib {u} (Compound) binds {v} (Gene) CYP1A1
Bortezomib {u} (Compound) upregulates {v} (Gene) CASP7
Bortezomib {u} (Compound) is included by {v} (Pharmacologic Class) Proteasome Inhibitors
Bortezomib {u} (Compound) downregulates {v} (Gene) CNDP2
Bortezomib {u} (Compound) causes {v} (Side Effect) Urinary retention
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Griseofulvin
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alefacept
Bortezomib (Compound) resembles Aspartame (Compound)
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Bortezomib (Compound) treats hematologic cancer (Disease)
Bortezomib (Compound) binds CYP1A1 (Gene)
Bortezomib (Compound) upregulates CASP7 (Gene)
Bortezomib (Compound) is included by Proteasome Inhibitors (Pharmacologic Class)
Bortezomib (Compound) downregulates CNDP2 (Gene)
Bortezomib (Compound) causes Urinary retention (Side Effect)
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Griseofulvin
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Alefacept